



# SENEGAL

Number of new cases

**11 841**

Number of deaths


**8 134**

Number of prevalent cases (5-year)

**23 512**


## Statistics at a glance, 2022

	Males	Females	Both sexes
<b>Population</b>	8 625 820	9 027 849	17 653 669
<b>Incidence*</b>			
Number of new cancer cases	4 270	7 571	11 841
Age-standardized incidence rate	99.0	126.9	113.9
Risk of developing cancer before the age of 75 years (cum. risk %)	10.5	12.9	11.8
<b>Top 3 leading cancers (ranked by cases)**</b>	Prostate Liver Stomach	Cervix uteri Breast Liver	Cervix uteri Breast Liver
<b>Mortality*</b>			
Number of cancer deaths	3 111	5 023	8 134
Age-standardized mortality rate	74.2	88.1	81.6
Risk of dying from cancer before the age of 75 years (cum. risk %)	7.8	9.4	8.7
<b>Top 3 leading cancers (ranked by deaths)**</b>	Liver Prostate Stomach	Cervix uteri Breast Liver	Cervix uteri Liver Breast
<b>Prevalence*</b>			
5-year prevalent cases	7 726	15 786	23 512



## Top 5 most frequent cancers\*\*


**Males**



Rank	Cancer site	Number of cases	Percent
1st	Prostate	913	21.4%
2nd	Liver	658	15.4%
3rd	Stomach	346	8.1%
4th	Colorectum	288	6.7%
5th	NHL	180	4.2%
-	Others	1 885	44.1%

Number of new cases in 2022, males, all ages


**Females**



Rank	Cancer site	Number of cases	Percent
1st	Cervix uteri	2 064	27.3%
2nd	Breast	1 838	24.3%
3rd	Liver	485	6.4%
4th	Stomach	334	4.4%
5th	Colorectum	321	4.2%
-	Others	2 529	33.4%

Number of new cases in 2022, females, all ages

**Both sexes**



Rank	Cancer site	Number of cases	Percent
1st	Cervix uteri	2 064	17.4%
2nd	Breast	1 838	15.5%
3rd	Liver	1 143	9.7%
4th	Prostate	913	7.7%
5th	Stomach	680	5.7%
-	Others	5 203	43.9%

Number of new cases in 2022, both sexes, all ages

Incidence, Mortality and Prevalence by cancer site

Cancer	New cases				Deaths				5-year prevalence	
	Number	Rank	(%)	Cum.risk	Number	Rank	(%)	Cum.risk	Number	Prop. (per 100 000)
Cervix uteri	2 064	1	17.4	3.6	1 327	1	16.3	2.6	4 532	50.2
Breast	1 838	2	15.5	3.1	976	3	12.0	1.8	4 063	45.0
Liver	1 143	3	9.7	1.2	1 127	2	13.9	1.2	1 775	10.1
Prostate	913	4	7.7	3.1	494	5	6.1	1.5	1 468	17.0
Stomach	680	5	5.7	0.85	599	4	7.4	0.76	1 126	6.4
Colorectum	609	6	5.1	0.68	432	6	5.3	0.49	1 228	7.0
NHL	325	7	2.7	0.23	210	8	2.6	0.18	766	4.3
Bladder	311	8	2.6	0.37	171	10	2.1	0.21	692	3.9
Ovary	269	9	2.3	0.48	188	9	2.3	0.40	557	6.2
Lung	259	10	2.2	0.31	240	7	3.0	0.29	422	2.4
Brain CNS	193	11	1.6	0.21	161	11	2.0	0.19	454	2.6
Lip, oral cavity	177	12	1.5	0.19	111	16	1.4	0.12	380	2.2
Kidney	171	13	1.4	0.12	116	15	1.4	0.10	401	2.3
Pancreas	166	14	1.4	0.21	160	12	2.0	0.21	213	1.2
Oesophagus	162	15	1.4	0.19	151	13	1.9	0.18	267	1.5
Leukaemia	150	16	1.3	0.12	118	14	1.5	0.10	323	1.8
Corpus uteri	128	17	1.1	0.30	47	18	0.58	0.10	301	3.3
Thyroid	115	18	0.97	0.12	46	19	0.57	0.07	257	1.5
Hodgkin lymphoma	85	19	0.72	0.05	37	23	0.46	0.03	218	1.2
Kaposi sarcoma	75	20	0.63	0.06	43	20	0.53	0.04	143	0.81
Larynx	59	21	0.50	0.08	38	22	0.47	0.05	120	0.68
Melanoma	59	21	0.50	0.08	20	27	0.25	0.03	133	0.75
Salivary glands	58	23	0.49	0.07	40	21	0.49	0.05	133	0.75
Multiple myeloma	56	24	0.47	0.08	48	17	0.59	0.07	118	0.67
Vulva	38	25	0.32	0.07	21	26	0.26	0.03	80	0.89
Gallbladder	30	26	0.25	0.03	29	24	0.36	0.03	53	0.30
Vagina	30	26	0.25	0.05	23	25	0.28	0.04	55	0.61
Nasopharynx	29	28	0.25	0.03	19	28	0.23	0.02	62	0.35
Oropharynx	19	29	0.16	0.02	12	29	0.15	0.02	37	0.21
Testis	13	30	0.11	0.03	4	30	0.05	0.00	33	0.38
Hypopharynx	6	31	0.05	0.01	4	30	0.05	0.01	8	0.05
Penis	3	32	0.03	0.00	2	32	0.03	0.00	7	0.08
<b>All cancers</b>	<b>11 841</b>	-	-	<b>11.8</b>	<b>8 134</b>	-	-	<b>8.7</b>	<b>23 512</b>	-
<b>All cancers excl. NMSC</b>	<b>11 561</b>	-	-	<b>11.5</b>	<b>8 025</b>	-	-	<b>8.5</b>	<b>22 829</b>	-

## Data source and methods

### Incidence

**Country-specific data source:** No data  
**Method:** No data: the rates are those of neighbouring countries or registries in the same area

[Click here to see detailed data source and methods](#)



### Mortality

**Country-specific data source:** Survival estimates  
**Method:** Estimated from national incidence estimates by modelling, using mortality:incidence ratios derived from survival estimation

[Click here to see detailed data source and methods](#)

### Prevalence

Computed using sex-, site- and age-specific incidence to 1-,3- and 5-year prevalence ratios from Nordic countries for the period (2011-2020), and scaled using Human Development Index (HDI) ratios.



\* includes non-melanoma skin cancer (NMSC)

\*\* NMSC included in other cancers

Age standardization using world population ([see link](#))

## References

### Website citation

Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2024). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: <https://gco.iarc.who.int/today>, accessed [DD Month YYYY].

### Cancer incidence and mortality data

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*. 2021 Feb 4. doi:10.3322/caac.21660. Epub ahead of print. PMID: 33538338.

Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, Bray F. Cancer statistics for the year 2020: An overview. *Int J Cancer*. 2021 Apr 5. doi:10.1002/ijc.33588. Epub ahead of print. PMID: 33818764.

